Riluzole to prevent thinking and memory problems during chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2a randomized, double-blind, placebo-controlled pilot gives adults receiving anthracycline- or platinum-containing chemotherapy either riluzole or placebo to see if riluzole reduces cognitive decline. Participants complete questionnaires and computerized neuropsychological assessments before, during, and after chemotherapy to measure changes in attention, memory, and executive function. Patients with primary brain tumors or brain metastases are excluded, and participants must have a life expectancy over six months and be able to provide informed consent. The single-site trial is conducted at the Chao Family Comprehensive Cancer Center at the University of California, Irvine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen.
* ≥18 years of age.
* Life expectancy \> 6 months
* Able to provide informed consent.
* Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.

Exclusion Criteria:

* Presence of primary brain tumors or brain metastases.
* Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy.
* Unwilling to undergo neuropsychological assessments necessary for the study.
* Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.
* History of or suspected hypersensitivity to riluzole or to any of its excipients.
* Patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.
* Hepatic impairment as indicated by: AST and/or ALT ≥ 3 X upper limit normal (ULN).
* Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.

Where it's running

• Chao Family Comprehensive Cancer Center, University of California Irvine
  Orange, California, United States Recruiting

Study contacts

• Principal investigator: Alexandre Chan, PharmD, MPH — Chao Family Comprehensive Cancer Center
• Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
• Email: ucstudy@uci.edu
• Phone: 877-827-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.